아토르바스타틴 칼슘 시장 : 형태별, 용도별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2024-2033년)

Atorvastatin Calcium Market By Form , By Application By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,252,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,473,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

아토르바스타틴 칼슘 시장은 2023년 2억 9,830만 달러로 평가되며, 2024-2033년 연평균 5% 성장하여 2033년에는 4억 8,780만 달러에 달할 것으로 예상됩니다.

아토르바스타틴 칼슘은 스타틴 계열의 약물로 심혈관질환 예방의 1차 선택 약물로 작용합니다. 간에서 콜레스테롤 합성에 중요한 역할을 하는 효소 HMG-CoA 환원효소를 억제하여 혈중 콜레스테롤 수치를 낮춥니다. 이 약은 저밀도 지단백(LDL) 콜레스테롤을 낮추는 데 효과적이며 고밀도 지단백(HDL) 콜레스테롤을 높이는 데도 도움이 됩니다. 콜레스테롤 수치를 관리함으로써 아토르바스타틴 칼슘은 심장마비, 뇌졸중 및 기타 심각한 심혈관질환을 예방하는 데 중요한 역할을 합니다.

세계 아토르바스타틴 칼슘 시장의 성장은 심혈관질환의 심각한 유병률 증가가 주요 요인으로 작용하고 있습니다. 세계 심장 연맹에 따르면 심혈관질환은 다른 어떤 원인보다 전 세계 사망 원인 중 1위이며, 2021년에는 전 세계적으로 약 2,050만 명이 사망할 것으로 보고되고 있습니다. 또한 노인 인구의 급격한 증가도 시장 성장에 크게 기여하고 있습니다. 이는 노인들이 고콜레스테롤혈증 및 관련 심혈관질환에 걸리기 쉽기 때문에 아토르바스타틴과 같은 콜레스테롤 저하제에 대한 수요가 증가하여 시장 성장을 촉진하고 있습니다. AHA 2019 Heart Disease and Stroke Statistical Update에 따르면, 60-79세의 심혈관질환 발병률은 남성 77.2%, 여성 78.2%로 보고되고 있습니다. 또한, 좌식 생활과 건강에 해로운 식습관의 증가는 인구의 콜레스테롤 수치 상승으로 이어져 아토르바스타틴 칼슘의 필요성이 증가하고 있습니다. 또한, 전반적인 건강을 위해 콜레스테롤 수치 관리의 중요성에 대한 대중의 인식이 높아지고 아토르바스타틴 칼슘의 제네릭 의약품이 출시되면서 세계 시장 성장에 기여하고 있습니다. 병용요법의 인기가 높아지는 것은 시장 성장을 증가시킬 것으로 예상되는 주요 트렌드입니다. 예를 들어, 아토르바스타틴 칼슘과 에제티미브(ezetimibe)와 같은 다른 약물과의 병용요법은 콜레스테롤 수치 관리의 치료 효과를 높이기 위해 보편화되고 있습니다. 그러나 근육통, 간 손상, 다른 약물과의 상호작용 등 아토르바스타틴 칼슘의 잠재적 부작용에 대한 우려가 커지면서 사용을 제한할 수 있어 시장 성장에 걸림돌로 작용하고 있습니다. 또한, 대체 스타틴 및 기타 콜레스테롤 저하제의 가용성 또한 세계 시장의 주요 억제요인으로 작용하고 있습니다. 반면, 제형 및 약물전달 시스템의 혁신은 아토르바스타틴 칼슘의 효능과 편의성을 향상시켜 예측 기간 동안 시장 성장에 유리한 기회를 제공할 것으로 예상됩니다.

세계 아토르바스타틴 칼슘 시장은 형태, 용도, 유통 채널 및 지역으로 분류됩니다. 형태에 따라 시장은 정제 및 기타로 분류됩니다. 용도별로는 고콜레스테롤혈증, 고지혈증, 기타로 구분됩니다. 유통 채널별로는 병원 약국, 드럭스토어 및 소매 약국, 온라인 제공업체로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

형태별로는 2023년에는 정제가, 2024년부터 2033년까지는 정제 형태가 시장을 장악할 것으로 예측됩니다.

용도별로는 고콜레스테롤혈증이 향후 몇 년 동안 세계 아토르바스타틴 칼슘 시장에서 유리한 부문이 될 것으로 예상됩니다.

유통 채널별로는 2033년까지 온라인 약국이 주요 부문으로 부상할 것으로 예상됩니다.

지역별로는 북미가 2023년 수익 측면에서 가장 큰 시장 점유율을 차지하며 예측 기간 동안 아토르바스타틴 칼슘 시장을 장악할 것으로 예상됩니다.

본 보고서에서 가능한 커스터마이징(추가 비용 및 일정이 있습니다.)

• 국가, 지역 및 세계 수준의 환자/역학 데이터
• 고객의 관심사에 따른 기업 프로파일 추가
• 기업 개요 확대 목록
• 과거 시장 데이터
• SWOT 분석

목차

제1장 소개

제2장 주요 요약

제3장 시장 상황

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 아토르바스타틴 칼슘 시장 : 형태별

• 시장 개요
• 정제
• 기타

제5장 아트라스틴카르시움 시장 : 용도별

• 시장 개요
• 고콜레스테롤혈증
• 고지혈증
• 기타

제6장 아토르바스타틴 칼슘 시장 : 유통 채널별

• 시장 개요
• 병원 약국
• 드럭스토어
• 온라인 프로바이더

제7장 아토르바스타틴 칼슘 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국의 아토르바스타틴 칼슘 시장
  • 캐나다의 아토르바스타틴 칼슘 시장
  • 멕시코의 아토르바스타틴 칼슘 시장
• 유럽
  • 주요 시장 동향과 기회
  • 프랑스의 아토르바스타틴 칼슘 시장
  • 독일의 아토르바스타틴 칼슘 시장
  • 이탈리아의 아토르바스타틴 칼슘 시장
  • 스페인의 아토르바스타틴 칼슘 시장
  • 영국의 아토르바스타틴 칼슘 시장
  • 기타 유럽 아토르바스타틴 칼슘 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 중국의 아토르바스타틴 칼슘 시장
  • 일본의 아토르바스타틴 칼슘 시장
  • 인도의 아토르바스타틴 칼슘 시장
  • 한국의 아토르바스타틴 칼슘 시장
  • 호주의 아토르바스타틴 칼슘 시장
  • 기타 아시아태평양의 아토르바스타틴 칼슘 시장
• 라틴아메리카, 중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질의 아토르바스타틴 칼슘 시장
  • 남아프리카공화국의 아토르바스타틴 칼슘 시장
  • 사우디아라비아의 아토르바스타틴 칼슘 시장
  • 기타 라틴아메리카, 중동 및 아프리카의 아토르바스타틴 칼슘 시장

제8장 경쟁 상황

• 소개
• 주요 성공 전략
• 주요 10개 기업 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제9장 기업 개요

• Mylan Pharmaceuticals Inc.
• Novartis AG
• GlaxoSmithKline Plc
• Amgen Inc.
• Sanofi SA
• Teva Pharmaceuticals Industries Ltd
• Merck And Co. Inc.
• Bristol-Myers Squibb Company
• AstraZeneca Plc
• Pfizer Inc.

ksm

영문 목차

영문목차

The atorvastatin calcium market was valued at $298.3 million in 2023, and is projected to reach $487.8 million by 2033, growing at a CAGR of 5% from 2024 to 2033.

Atorvastatin calcium is a statin medication, which acts as the first line of treatment for the prevention of cardiovascular diseases. It lowers the cholesterol levels in the blood by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver. This medication is effective in lowering low-density lipoprotein (LDL) cholesterol, and can also help to raise high-density lipoprotein (HDL) cholesterol. By managing cholesterol levels, atorvastatin calcium plays a crucial role in preventing heart attacks, strokes, and other serious cardiovascular events.

The growth of the global atorvastatin calcium market is majorly driven by alarming increase in prevalence of cardiovascular diseases. According to the World Heart Federation, cardiovascular diseases are the leading cause of death worldwide as compared to any other cause. Approximately 20.5 million deaths were reported in 2021 across the globe. In addition, surge in geriatric population significantly contributes toward the market growth. This is attributed to the fact that aged individuals are highly susceptible to hypercholesterolemia and related cardiovascular conditions, which, in turn, leads to higher demand for cholesterol-lowering medications like atorvastatin, thereby boosting the market growth. As per AHA 2019 Heart Disease and Stroke Statistical Update, the incidence of cardiovascular diseases was reported to be 77.2% in males and 78.2% in females, from ages 60-79 years. Moreover, rise in sedentary lifestyles and unhealthy eating patterns are leading to higher cholesterol levels among the population, thereby increasing the need for atorvastatin calcium. Furthermore, rise in public awareness of the importance of managing cholesterol levels for overall health and availability of generic versions of atorvastatin calcium boost the growth of the global market. Increase in popularity of combination therapies acts a key trend that is expected to augment the market growth. For instance, the use of atorvastatin calcium in combination with other drugs, such as ezetimibe, is becoming more common to enhance therapeutic outcomes for managing cholesterol levels. However, rise in concerns about potential side effects of atorvastatin calcium such as muscle pain, liver damage, and interactions with other medications can limit its use, which hampers the market growth. In addition, availability of alternative statins and other cholesterol-lowering drugs acts as key deterrent factor of the global market. On the contrary, innovations in drug formulation and delivery systems are enhancing the efficacy and convenience of atorvastatin calcium, which are expected to offer lucrative opportunities for the market growth during the forecast period.

The global atorvastatin calcium market is segmented into form, application, distribution channel, and region. On the basis of form, the market is categorized into tablets and others. By application, it is divided into hypercholesterolemia, hyperlipidemia, and others. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of form, the tablets segment dominated the market in 2023, and is is expected to dominate from 2024 to 2033.

By application, hypercholesterolemia is anticipated to be the lucrative segment in the global atorvastatin calcium market in the coming years.

Depending on distribution channel, online pharmacies is projected to emerge as the leading segment by 2033.

Region wise, North America held the largest market share in terms of revenue in 2023, and is expected to dominate the atorvastatin calcium market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global atorvastatin calcium market include Mylan Pharmaceuticals Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd, Merck and Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc., and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Patient/epidemiology data at country, region, global level
• Additional company profiles with specific to client's interest
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Form

• Tablets
• Others

By Application

• Hypercholesterolemia
• Hyperlipidemia
• Others

By Distribution Channel

• Hospital pharmacies
• Drug store retail pharmacies
• Online providers.

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players:

• Mylan Pharmaceuticals Inc.
• Novartis AG
• GlaxoSmithKline plc
• Amgen Inc.
• Sanofi SA
• Teva Pharmaceuticals Industries Ltd
• Merck and Co. Inc.
• Bristol-Myers Squibb Company
• AstraZeneca Plc
• Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: ATORVASTATIN CALCIUM MARKET, BY FORM

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Form
• 4.2. Tablets
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. Others
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: ATORVASTATIN CALCIUM MARKET, BY APPLICATION

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Application
• 5.2. Hypercholesterolemia
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. Hyperlipidemia
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country
• 5.4. Others
  • 5.4.1. Key Market Trends, Growth Factors and Opportunities
  • 5.4.2. Market Size and Forecast, By Region
  • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By Distribution Channel
• 6.2. Hospital Pharmacies
  • 6.2.1. Key Market Trends, Growth Factors and Opportunities
  • 6.2.2. Market Size and Forecast, By Region
  • 6.2.3. Market Share Analysis, By Country
• 6.3. Drug Store Retail Pharmacies
  • 6.3.1. Key Market Trends, Growth Factors and Opportunities
  • 6.3.2. Market Size and Forecast, By Region
  • 6.3.3. Market Share Analysis, By Country
• 6.4. Online Providers.
  • 6.4.1. Key Market Trends, Growth Factors and Opportunities
  • 6.4.2. Market Size and Forecast, By Region
  • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: ATORVASTATIN CALCIUM MARKET, BY REGION

• 7.1. Market Overview
  • 7.1.1 Market Size and Forecast, By Region
• 7.2. North America
  • 7.2.1. Key Market Trends and Opportunities
  • 7.2.2. Market Size and Forecast, By Form
  • 7.2.3. Market Size and Forecast, By Application
  • 7.2.4. Market Size and Forecast, By Distribution Channel
  • 7.2.5. Market Size and Forecast, By Country
  • 7.2.6. U.S. Atorvastatin Calcium Market
    • 7.2.6.1. Market Size and Forecast, By Form
    • 7.2.6.2. Market Size and Forecast, By Application
    • 7.2.6.3. Market Size and Forecast, By Distribution Channel
  • 7.2.7. Canada Atorvastatin Calcium Market
    • 7.2.7.1. Market Size and Forecast, By Form
    • 7.2.7.2. Market Size and Forecast, By Application
    • 7.2.7.3. Market Size and Forecast, By Distribution Channel
  • 7.2.8. Mexico Atorvastatin Calcium Market
    • 7.2.8.1. Market Size and Forecast, By Form
    • 7.2.8.2. Market Size and Forecast, By Application
    • 7.2.8.3. Market Size and Forecast, By Distribution Channel
• 7.3. Europe
  • 7.3.1. Key Market Trends and Opportunities
  • 7.3.2. Market Size and Forecast, By Form
  • 7.3.3. Market Size and Forecast, By Application
  • 7.3.4. Market Size and Forecast, By Distribution Channel
  • 7.3.5. Market Size and Forecast, By Country
  • 7.3.6. France Atorvastatin Calcium Market
    • 7.3.6.1. Market Size and Forecast, By Form
    • 7.3.6.2. Market Size and Forecast, By Application
    • 7.3.6.3. Market Size and Forecast, By Distribution Channel
  • 7.3.7. Germany Atorvastatin Calcium Market
    • 7.3.7.1. Market Size and Forecast, By Form
    • 7.3.7.2. Market Size and Forecast, By Application
    • 7.3.7.3. Market Size and Forecast, By Distribution Channel
  • 7.3.8. Italy Atorvastatin Calcium Market
    • 7.3.8.1. Market Size and Forecast, By Form
    • 7.3.8.2. Market Size and Forecast, By Application
    • 7.3.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3.9. Spain Atorvastatin Calcium Market
    • 7.3.9.1. Market Size and Forecast, By Form
    • 7.3.9.2. Market Size and Forecast, By Application
    • 7.3.9.3. Market Size and Forecast, By Distribution Channel
  • 7.3.10. UK Atorvastatin Calcium Market
    • 7.3.10.1. Market Size and Forecast, By Form
    • 7.3.10.2. Market Size and Forecast, By Application
    • 7.3.10.3. Market Size and Forecast, By Distribution Channel
  • 7.3.11. Rest of Europe Atorvastatin Calcium Market
    • 7.3.11.1. Market Size and Forecast, By Form
    • 7.3.11.2. Market Size and Forecast, By Application
    • 7.3.11.3. Market Size and Forecast, By Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key Market Trends and Opportunities
  • 7.4.2. Market Size and Forecast, By Form
  • 7.4.3. Market Size and Forecast, By Application
  • 7.4.4. Market Size and Forecast, By Distribution Channel
  • 7.4.5. Market Size and Forecast, By Country
  • 7.4.6. China Atorvastatin Calcium Market
    • 7.4.6.1. Market Size and Forecast, By Form
    • 7.4.6.2. Market Size and Forecast, By Application
    • 7.4.6.3. Market Size and Forecast, By Distribution Channel
  • 7.4.7. Japan Atorvastatin Calcium Market
    • 7.4.7.1. Market Size and Forecast, By Form
    • 7.4.7.2. Market Size and Forecast, By Application
    • 7.4.7.3. Market Size and Forecast, By Distribution Channel
  • 7.4.8. India Atorvastatin Calcium Market
    • 7.4.8.1. Market Size and Forecast, By Form
    • 7.4.8.2. Market Size and Forecast, By Application
    • 7.4.8.3. Market Size and Forecast, By Distribution Channel
  • 7.4.9. South Korea Atorvastatin Calcium Market
    • 7.4.9.1. Market Size and Forecast, By Form
    • 7.4.9.2. Market Size and Forecast, By Application
    • 7.4.9.3. Market Size and Forecast, By Distribution Channel
  • 7.4.10. Australia Atorvastatin Calcium Market
    • 7.4.10.1. Market Size and Forecast, By Form
    • 7.4.10.2. Market Size and Forecast, By Application
    • 7.4.10.3. Market Size and Forecast, By Distribution Channel
  • 7.4.11. Rest of Asia-Pacific Atorvastatin Calcium Market
    • 7.4.11.1. Market Size and Forecast, By Form
    • 7.4.11.2. Market Size and Forecast, By Application
    • 7.4.11.3. Market Size and Forecast, By Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key Market Trends and Opportunities
  • 7.5.2. Market Size and Forecast, By Form
  • 7.5.3. Market Size and Forecast, By Application
  • 7.5.4. Market Size and Forecast, By Distribution Channel
  • 7.5.5. Market Size and Forecast, By Country
  • 7.5.6. Brazil Atorvastatin Calcium Market
    • 7.5.6.1. Market Size and Forecast, By Form
    • 7.5.6.2. Market Size and Forecast, By Application
    • 7.5.6.3. Market Size and Forecast, By Distribution Channel
  • 7.5.7. South Africa Atorvastatin Calcium Market
    • 7.5.7.1. Market Size and Forecast, By Form
    • 7.5.7.2. Market Size and Forecast, By Application
    • 7.5.7.3. Market Size and Forecast, By Distribution Channel
  • 7.5.8. Saudi Arabia Atorvastatin Calcium Market
    • 7.5.8.1. Market Size and Forecast, By Form
    • 7.5.8.2. Market Size and Forecast, By Application
    • 7.5.8.3. Market Size and Forecast, By Distribution Channel
  • 7.5.9. Rest of LAMEA Atorvastatin Calcium Market
    • 7.5.9.1. Market Size and Forecast, By Form
    • 7.5.9.2. Market Size and Forecast, By Application
    • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top Winning Strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. Mylan Pharmaceuticals Inc.
  • 9.1.1. Company Overview
  • 9.1.2. Key Executives
  • 9.1.3. Company Snapshot
  • 9.1.4. Operating Business Segments
  • 9.1.5. Product Portfolio
  • 9.1.6. Business Performance
  • 9.1.7. Key Strategic Moves and Developments
• 9.2. Novartis AG
  • 9.2.1. Company Overview
  • 9.2.2. Key Executives
  • 9.2.3. Company Snapshot
  • 9.2.4. Operating Business Segments
  • 9.2.5. Product Portfolio
  • 9.2.6. Business Performance
  • 9.2.7. Key Strategic Moves and Developments
• 9.3. GlaxoSmithKline Plc
  • 9.3.1. Company Overview
  • 9.3.2. Key Executives
  • 9.3.3. Company Snapshot
  • 9.3.4. Operating Business Segments
  • 9.3.5. Product Portfolio
  • 9.3.6. Business Performance
  • 9.3.7. Key Strategic Moves and Developments
• 9.4. Amgen Inc.
  • 9.4.1. Company Overview
  • 9.4.2. Key Executives
  • 9.4.3. Company Snapshot
  • 9.4.4. Operating Business Segments
  • 9.4.5. Product Portfolio
  • 9.4.6. Business Performance
  • 9.4.7. Key Strategic Moves and Developments
• 9.5. Sanofi SA
  • 9.5.1. Company Overview
  • 9.5.2. Key Executives
  • 9.5.3. Company Snapshot
  • 9.5.4. Operating Business Segments
  • 9.5.5. Product Portfolio
  • 9.5.6. Business Performance
  • 9.5.7. Key Strategic Moves and Developments
• 9.6. Teva Pharmaceuticals Industries Ltd
  • 9.6.1. Company Overview
  • 9.6.2. Key Executives
  • 9.6.3. Company Snapshot
  • 9.6.4. Operating Business Segments
  • 9.6.5. Product Portfolio
  • 9.6.6. Business Performance
  • 9.6.7. Key Strategic Moves and Developments
• 9.7. Merck And Co. Inc.
  • 9.7.1. Company Overview
  • 9.7.2. Key Executives
  • 9.7.3. Company Snapshot
  • 9.7.4. Operating Business Segments
  • 9.7.5. Product Portfolio
  • 9.7.6. Business Performance
  • 9.7.7. Key Strategic Moves and Developments
• 9.8. Bristol-Myers Squibb Company
  • 9.8.1. Company Overview
  • 9.8.2. Key Executives
  • 9.8.3. Company Snapshot
  • 9.8.4. Operating Business Segments
  • 9.8.5. Product Portfolio
  • 9.8.6. Business Performance
  • 9.8.7. Key Strategic Moves and Developments
• 9.9. AstraZeneca Plc
  • 9.9.1. Company Overview
  • 9.9.2. Key Executives
  • 9.9.3. Company Snapshot
  • 9.9.4. Operating Business Segments
  • 9.9.5. Product Portfolio
  • 9.9.6. Business Performance
  • 9.9.7. Key Strategic Moves and Developments
• 9.10. Pfizer Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Key Executives
  • 9.10.3. Company Snapshot
  • 9.10.4. Operating Business Segments
  • 9.10.5. Product Portfolio
  • 9.10.6. Business Performance
  • 9.10.7. Key Strategic Moves and Developments

관련자료